�United
Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary
Lung Rx, Inc. announced that the U.S. Food and Drug Administration
(FDA) has accepted for review the New Drug Application (NDA) for inhaled
treprostinil for the treatment of pulmonary arterial high blood pressure. The NDA
will be subject to a standard review time period of 10 months, with a targeted
user fee deadline of April 30, 2009.
United Therapeutics Corporation is a biotechnology company focused on
the evolution and commercialization of unique products to address the
unmet medical needs of patients with chronic and life-threatening
cardiovascular and infectious diseases and cancer.
Lung Rx, Inc. is a biotechnology ship's company focused on unmet medical needs
in pulmonary medical specialty and pneumonic delivery of innovative remedial
products. [uthr-g]
United Therapeutics Corporation
http://www.unither.com
More information
